Group 1 - The company approved the acquisition of a 51% stake in Honghui Pharmaceutical Co., Ltd. for a total consideration of RMB 104.6372 million [2] - The acquisition agreement was initially signed with multiple parties, including Honghui Technology and Beijing Daopai Hongde Medical Investment Co., Ltd. [2] - Due to triggering audit clauses and profit fluctuation factors, the execution of the acquisition agreement was suspended, and the parties agreed to renegotiate the terms [3] Group 2 - The parties reached a consensus on the execution of the supplementary agreement, which includes the commitment from Honghui Pharmaceutical to change its name by July 31, 2025 [4] - Honghui Technology is required to refund the intention payment of RMB 52.3186 million to the company within five working days after signing the execution agreement [4] - The company will return the acquired 51% stake back to the original shareholder, Honghui Technology, after fulfilling the necessary approval procedures [4] Group 3 - The execution agreement confirms the specific execution of the acquisition and will not have a significant impact on the company's financial status or operating results [5] - The agreement is seen as beneficial for controlling investment risks and protecting the interests of all shareholders [5] - The company will continue to disclose information regarding the progress of this investment in accordance with relevant regulations [5]
北京同仁堂股份有限公司关于对外投资的进展公告